PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
8.95%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.25%. Joel Greenblatt would investigate if growth quality matches quantity.
10.24%
Cost growth of 10.24% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
3.35%
Growth of 3.35% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
-5.14%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.32%
Other expenses change of 5.32% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
9.03%
Operating expenses growth 1.25-1.5x Medical - Pharmaceuticals median of 7.04%. Guy Spier would scrutinize spending.
10.06%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 5.44%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
6.28%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.08%. Jim Chanos would check for overinvestment.
-4.69%
EBITDA decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-12.52%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-15.56%
Operating income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-22.50%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
117.43%
Other expenses change of 117.43% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
-4.70%
Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-12.53%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-15.95%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
4.01%
Income change of 4.01% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-4.53%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
4.00%
EPS change of 4.00% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
4.00%
Diluted EPS change of 4.00% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.04%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.04%. Seth Klarman would investigate strategy.